secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0000014272-24-000121
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance
-------------------------------------------------------------------------

- Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
- GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.
- Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.
- Subcutaneous nivolumab under regulatory review in U.S. and E.U.
- CEO Boerner cited progress on commercial execution and pipeline advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/0000014272-24-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/bmy-20240726.htm
  HTML page:      https://secwatch.observer/filing/0000014272-24-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer